11 results on '"B. Gonzalez-Farre"'
Search Results
2. 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)
3. 10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)
4. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer
5. PEDIATRIC NODAL MARGINAL ZONE LYMPHOMA AND PEDIATRIC-TYPE FOLLICULAR LYMPHOMA SHARE A COMMON MOLECULAR PROFILE
6. 132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy
7. 202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
8. LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
9. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy
10. 6P The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients: Results from AWARE-1 study
11. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.